+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Kaposi Sarcoma Market by Type, Drug Class, Treatment, Mode of Treatment - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888876
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Kaposi Sarcoma Market grew from USD 140.29 million in 2023 to USD 145.55 million in 2024. It is expected to continue growing at a CAGR of 3.73%, reaching USD 181.40 million by 2030.

Kaposi Sarcoma (KS) is a type of cancer that forms in the lining of blood and lymph vessels, presenting as tumors on the skin or mucosal surfaces, and is closely associated with human herpesvirus 8 (HHV-8) infection. The necessity for market research in this area arises from the requirement to understand disease prevalence, patient demographics, and advancements in therapeutic interventions, which are essential for shaping healthcare outcomes and driving investments. Applications are mainly found in healthcare sectors focusing on oncology, and end-users include pharmaceutical companies, research institutions, and healthcare providers. Key influencing factors for market growth include technological advancements in diagnostic and therapeutic approaches, increased healthcare spending, and patient awareness. Notably, the rise in research funding for rare diseases and strategic collaborations among key players amplify growth potential. Opportunities in this market lie in the development of targeted therapies and vaccines against HHV-8, as well as in leveraging AI and machine learning for early detection and personalized medicine. However, market growth is hampered by high treatment costs, lack of widespread awareness, and limited access to advanced therapies in underdeveloped regions. Furthermore, regulatory and reimbursement challenges persist across various geographies. Innovation can pivot towards developing cost-effective, accessible treatment options and enhancing early diagnostic tools, with digital health technologies poised as a promising frontier. Businesses should also consider integrating genomic data analytics into their R&D strategies to facilitate breakthrough discoveries. The nature of the KS market is niche yet dynamic, with developments in immune-oncology and precision medicine offering substantial growth avenues. Continued investment in clinical trials, along with fostering public-private partnerships, can support advancing treatment paradigms and guide strategic imperatives towards tapping the unmet needs in KS management.

Understanding Market Dynamics in the Kaposi Sarcoma Market

The Kaposi Sarcoma Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of HIV-associated Kaposi Sarcoma
    • Rising number of patients undergoing organ transplantation procedures
    • Growing number of clinical studies related to Kaposi Sarcoma disease
  • Market Restraints
    • High cost associated with diagnosis of Kaposi Sarcoma treatment
  • Market Opportunities
    • Investment in R&D activities for Kaposi Sarcoma treatment
    • Introduction of advanced highly active antiretroviral treatment
  • Market Challenges
    • Lack of skilled workforce and shortage in the supply of drugs

Exploring Porter’s Five Forces for the Kaposi Sarcoma Market

Porter’s Five Forces framework further strengthens the insights of the Kaposi Sarcoma Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Kaposi Sarcoma Market

External macro-environmental factors deeply influence the performance of the Kaposi Sarcoma Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Kaposi Sarcoma Market

The Kaposi Sarcoma Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Kaposi Sarcoma Market

The Kaposi Sarcoma Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Kaposi Sarcoma Market

The Kaposi Sarcoma Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kaposi Sarcoma Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals LLC, Aphios Corporation, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Getwell Oncology Pvt Ltd, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, John Wiley & Sons, Inc., Johnson & Johnson Services, Inc, Lupin Ltd., Merck & Co., Inc, Mylan N.V., Navidea Biopharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Kaposi Sarcoma Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Classic (Mediterranean) Kaposi Sarcoma
    • Endemic (African) Kaposi Sarcoma
    • Epidemic (AIDS-associated) Kaposi Sarcoma
    • Iatrogenic (Transplant-Related) Kaposi Sarcoma
  • Drug Class
    • Doxil (Doxorubicin Hydrochloride Liposome)
    • Doxorubicin Hydrochloride Liposome
    • Intron A (Recombinant Interferon Alfa-2b)
    • Paclitaxel
    • Pomalidomide
    • Pomalyst (Pomalidomide)
    • Recombinant Interferon Alfa-2b
    • Vinblastine Sulfate
  • Treatment
    • Biological Therapy
    • Chemotherapy
    • Cryosurgery
    • HAART
    • Radiation Therapy
    • Surgery
    • Treatment
  • Mode of Treatment
    • Chemotherapy
    • Intralesional Injection
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of HIV-associated Kaposi Sarcoma
5.1.1.2. Rising number of patients undergoing organ transplantation procedures
5.1.1.3. Growing number of clinical studies related to Kaposi Sarcoma disease
5.1.2. Restraints
5.1.2.1. High cost associated with diagnosis of Kaposi Sarcoma treatment
5.1.3. Opportunities
5.1.3.1. Investment in R&D activities for Kaposi Sarcoma treatment
5.1.3.2. Introduction of advanced highly active antiretroviral treatment
5.1.4. Challenges
5.1.4.1. Lack of skilled workforce and shortage in the supply of drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Kaposi Sarcoma Market, by Type
6.1. Introduction
6.2. Classic (Mediterranean) Kaposi Sarcoma
6.3. Endemic (African) Kaposi Sarcoma
6.4. Epidemic (AIDS-associated) Kaposi Sarcoma
6.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma
7. Kaposi Sarcoma Market, by Drug Class
7.1. Introduction
7.2. Doxil (Doxorubicin Hydrochloride Liposome)
7.3. Doxorubicin Hydrochloride Liposome
7.4. Intron A (Recombinant Interferon Alfa-2b)
7.5. Paclitaxel
7.6. Pomalidomide
7.7. Pomalyst (Pomalidomide)
7.8. Recombinant Interferon Alfa-2b
7.9. Vinblastine Sulfate
8. Kaposi Sarcoma Market, by Treatment
8.1. Introduction
8.2. Biological Therapy
8.3. Chemotherapy
8.4. Cryosurgery
8.5. HAART
8.6. Radiation Therapy
8.7. Surgery
8.8. Treatment
9. Kaposi Sarcoma Market, by Mode of Treatment
9.1. Introduction
9.2. Chemotherapy
9.3. Intralesional Injection
10. Americas Kaposi Sarcoma Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Kaposi Sarcoma Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Kaposi Sarcoma Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. KAPOSI SARCOMA MARKET RESEARCH PROCESS
FIGURE 2. KAPOSI SARCOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2030 (%)
FIGURE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. KAPOSI SARCOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. KAPOSI SARCOMA MARKET DYNAMICS
TABLE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC (MEDITERRANEAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC (AFRICAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC (AIDS-ASSOCIATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC (TRANSPLANT-RELATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRON A (RECOMBINANT INTERFERON ALFA-2B), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALYST (POMALIDOMIDE), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RECOMBINANT INTERFERON ALFA-2B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VINBLASTINE SULFATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BIOLOGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HAART, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRALESIONAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. CANADA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. CANADA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. CANADA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. MEXICO KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CHINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. CHINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. CHINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. CHINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. INDIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. INDIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. INDIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. INDIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. JAPAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. THAILAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. THAILAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. DENMARK KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. DENMARK KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. EGYPT KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. EGYPT KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. FINLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. FINLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. FRANCE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. GERMANY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. ITALY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. ITALY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. ITALY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. ITALY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 151. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. NORWAY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. NORWAY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. POLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. POLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. POLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. POLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. QATAR KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. QATAR KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. QATAR KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 163. QATAR KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 179. SPAIN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. TURKEY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 191. TURKEY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 200. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 201. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Kaposi Sarcoma Market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aphios Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • John Wiley & Sons, Inc.
  • Johnson & Johnson Services, Inc
  • Lupin Ltd.
  • Merck & Co., Inc
  • Mylan N.V.
  • Navidea Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information